Navigation Links
SGX Pharmaceuticals Provides Update on SGX523 Clinical Trials
Date:3/27/2008

Company Presents Today at BioCentury Future Leaders Conference

SAN DIEGO, March 27 /PRNewswire-FirstCall/ -- SGX Pharmaceuticals (Nasdaq: SGXP) is providing an update today on the SGX523 clinical program.

In January 2008, the Company initiated two parallel, multi-center Phase 1 clinical trials of SGX523 in patients with solid tumor cancers. The first trial has been designed to examine twice daily, oral dosing on a continuous 28-day cycle and the second trial has been designed to examine interrupted dosing (a repeating 21 day cycle of 14 days on therapy followed by 7 days off).

In both trials, the Company observed dose limiting toxicity earlier than anticipated. The toxicity is of a nature that was not anticipated based on the preclinical profile of SGX523. The interrupted dosing trial started at a higher dose than the continuous dosing trial and no patients are currently receiving treatment on the interrupted dosing trial. In the continuous dosing trial, patients are continuing to be treated at a lower dose level, and the Company is evaluating the safety and efficacy of treatment at that dose level.

"From the initial clinical data, the profile of SGX523 appears to be different than the preclinical data would suggest," said Mike Grey, president and chief executive officer of SGX Pharmaceuticals. "On the continuous dosing trial, patients continue on study at the initial dose and we may explore whether alternative doses and schedules are safe and efficacious. We continue the preclinical development of the BCR-ABL inhibitor SGX393 and the second MET inhibitor SGX126. In addition, we are targeting the identification of two development candidates this year from our drug discovery programs to further enhance our pi
'/>"/>

SOURCE SGX Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Alseres Pharmaceuticals to Host 2007 Financial Results Conference Call
2. Millennium Biotechnologies, Inc. Signs Marketing and Distribution Agreement with Ferring Pharmaceuticals
3. Nereus Pharmaceuticals Initiates Clinical Trial of NPI-2358 in Non-Small Cell Lung Cancer Following Encouraging Phase 1 Data
4. XTL Biopharmaceuticals Signs $108 Million Deal for the Licensing of its Pre- Clinical Program in Hepatitis C to Presidio Pharmaceuticals
5. SGX Pharmaceuticals to Present at the BioCentury Future Leaders in the Biotech Industry Conference
6. Raptor Pharmaceuticals Corp. Enters Agreements to Advance Clinical Pipeline
7. LigoCyte Pharmaceuticals Finalizes Agreement for $28M Series C Financing Round
8. Jazz Pharmaceuticals, Inc. Announces Expansion of Senior Debt
9. Vion Pharmaceuticals to Host Conference Call to Discuss 2007 Fourth Quarter and Year-End Financial Results
10. MiddleBrook Pharmaceuticals to Present at Lehman Brothers Global Healthcare Conference
11. Cadence Pharmaceuticals to Present at the Cowen and Company 28th Annual Health Care Conference on March 20, 2008 in Boston
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... 18, 2013 Edison ... firm, announces the initiation of full coverage ... company developing and marketing products for orphan ...      (Logo: http://photos.prnewswire.com/prnh/20130417/608168) Edison ... the investment merits of BioAlliance Pharma, focusing ...
(Date:6/18/2013)...  Techne Corporation (NASDAQ: TECH ) ... acquire 100% ownership of Bionostics Holdings Limited and ... a global leader in the development, manufacture and ... operation of in vitro diagnostic (IVD) ... glucose and blood gas testing.  Biosnostics has strategic ...
(Date:6/18/2013)... Texas , June 18, 2013   ... ), a biopharmaceutical company focused on discovering breakthrough ... John Northcott has joined the company as ... operations. Mr. Northcott brings extensive commercial experience to ... across a variety of therapeutic areas. ...
(Date:6/18/2013)... Inflamax Research Inc., a full ... Phase I-IV clinical trials, announced today that they ... Environmental Technologies (NAET), a specialty air conditioning & ... servicing of mobile Environmental Exposure Chambers (EECs) used ... , Inflamax Research has proprietary Next ...
Breaking Biology Technology:Edison Expands French Healthcare Sector Coverage With Initiation of Coverage on BioAlliance Pharma 2Edison Expands French Healthcare Sector Coverage With Initiation of Coverage on BioAlliance Pharma 3Techne Corporation Announces Acquisition Agreement 2Techne Corporation Announces Acquisition Agreement 3Techne Corporation Announces Acquisition Agreement 4Techne Corporation Announces Acquisition Agreement 5John Northcott Joins Lexicon as Vice President of Marketing, Commercial Strategy and Operations 2John Northcott Joins Lexicon as Vice President of Marketing, Commercial Strategy and Operations 3Inflamax Research Inc. Enters Strategic Partnership with Northern Air Environmental Technologies Inc. 2Inflamax Research Inc. Enters Strategic Partnership with Northern Air Environmental Technologies Inc. 3
... the American Cancer Society, one in three people will ... lifetime. In an effort to improve patient care and ... has developed innovative medical imaging technologies that are allowing ... disease. , ,The latest cancer-fighting advancements from GE ...
... -- SoftSwitching Technologies' nationwide power-monitoring system is ... Outage Task Force in its newly released report ... that affected large portions of the Midwest and Northeast ... Federal Energy Regulatory Commission (FERC) and the Task Force ...
... Note: This is the first of a multi-part interview ... , managing director of the Wisconsin Alumni Research Foundation ... WARF initiative called Whats in it for Wisconsin Business. This ... foundation more accessible to companies throughout the state, as well ...
Cached Biology Technology:GE Medicals Technologies Aid Battle Against Cancer 2GE Medicals Technologies Aid Battle Against Cancer 3WTN Interviews: How WARF is Reaching Out to Businesses About Technology Developed in Wisconsin 2WTN Interviews: How WARF is Reaching Out to Businesses About Technology Developed in Wisconsin 3WTN Interviews: How WARF is Reaching Out to Businesses About Technology Developed in Wisconsin 4
(Date:6/18/2013)... in the Gulf of Mexico and a smaller than ... based on several NOAA-supported forecast models. , NOAA-supported modelers ... the Louisiana Universities Marine Consortium are forecasting that ... be between 7,286 and 8,561 square miles which could ... range from an area the size of Connecticut, Rhode ...
(Date:6/18/2013)... Washington, D.C. June 18, 2013 Joshua Obar, ... UniversityBozeman, has been honored with a 2013 ICAAC Young ... the regulation of immunological memory responses to infection. ... Wesleyan University in 2001 and went on to complete ... in 2006. He performed his Ph.D. thesis research ...
(Date:6/18/2013)... 5% and 10% of breast and ovarian cancers are ... tumours are attributable to inherited mutations from the parents ... with these mutations, PARP inhibitors, which are currently in ... a new option for personalised cancer treatment, an alternative ... a fraction of these patients generate resistance to the ...
Breaking Biology News(10 mins):NOAA, partners predict possible record-setting deadzone for Gulf of Mexico 2NOAA, partners predict possible record-setting deadzone for Gulf of Mexico 3NOAA, partners predict possible record-setting deadzone for Gulf of Mexico 4The American Society for Microbiology honors Joshua Obar 2An article in 'Cell' reveals a new resistance mechanism to chemotherapy in breast and ovarian cancer 2
... response to an avian influenza vaccine with doses as ... a chemical mixture known as MF59. The research is ... Diseases, now available online. , MF 59 is ... to respond to a stimulus. For this research, the ...
... of endangered bird eggs made international headlines in May ... illegal egg collector, died after falling from a 12-meter ... Society for the Protection of Birds estimates that up ... by collectors. Classical economics theory predicts that such exploitation ...
... switch, the hepatitis C virus turns on human immune ... those defenses by manipulating interaction of key cellular proteins, ... This same molecular "on/off switch" controls immunity against many ... to fight viruses, the researchers report. , In ...
Cached Biology News:A human taste for rarity spells disaster for endangered species 2A human taste for rarity spells disaster for endangered species 3Molecular 'on/off switch' controls immune defenses against viruses 2
... Immunogen KLH-conjugated, synthetic ... 47-66 (PAEV-GPGAVGERTPRKKEPP) of human BRAF-HDAC ... (BHC110/LSD1). Quality Assurance ... Stability 2 years ...
Request Info...
...
...
Biology Products: